Clinical trials: Allogeneic Stem-Cell Transplant
Adult Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
This phase II trial studies how well fludarabine and busulfan followed by a donor (allogeneic) stem cell transplant work in treating older patients with acute myeloid leukemia that is in first complete remission.
- Trial name
- NCT00070135
- Testing
- filgrastim, Anti-Thymocyte Globulin, busulfan
- Where
- 21 sites in United States
- Volunteers
- 121 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
CMV-CMI in csCMVi After HSCT
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key…
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
- Trial name
- NCT07688759
- Testing
- Anti-Cytomegalovirus Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Allogeneic Stem Cell Transplant Recipient
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
The Flu-TBI 800 trial is a prospective, single-arm, multicenter, interventional phase 2 study to evaluate whether fludarabine plus intermediate-dose total body irradiation (TBI 800 cGy) with post-transplant cyclophosphamide…
- Trial name
- NCT07214688
- Testing
- Fludarabine, Intermediate-dose Total Body Irradiation (TBI), Post-transplant Cyclophosphamide (PTCy)
- Where
- 3 sites in United States
- Volunteers
- 209 people
- Sponsor
- Hackensack Meridian Health
Hematopoietic Stem Cell Transplantation
Dysbiosis and Immune Reconstitution After Allo-HSCT
Preliminary (proof of concept), monocentric, interventional, prospective, non-randomized and analytic trial designed to simultaneously explore intestinal microbiota changes and early post-transplant immune reconstitution, and to…
- Trial name
- PARI-DYS (NCT03616015)
- Testing
- blood samples, fecal samples, Anxiety test
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Central Hospital, Nancy, France
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
Targeted immune therapy with gemtuzumab ozogamicin (Mylotarg) in combination with chemotherapy followed by allogeneic stem cell transplantation will be given to patients with high risk acute myelogenous leukemia (AML) or…
- Trial name
- NCT02221310
- Testing
- Gemtuzumab Ozogamicin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- New York Medical College
Myeloid Malignancies
Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies
The experimental treatment consists in the application of a therapeutic strategy with post Transplant High-Dose Cyclophosphamide as GvHD Prophylaxis in Patients Receiving 1-Antigen/Allele HLA Mismatched (7/8 matched) Unrelated…
- Trial name
- GITMO-PHYLOS (NCT03270748)
- Testing
- GvHD prophylaxis
- Where
- 33 sites in Italy
- Volunteers
- 78 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hematological Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Hetrombopag for the Enhancement of Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation
This investigator-initiated, prospective, multicenter, open-label, randomized, controlled clinical study is designed to evaluate the clinical efficacy and safety of hetrombopag for promoting platelet engraftment after allo-HSCT…
- Trial name
- NCT05727917
- Testing
- Hetrombopag
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft Versus Host Disease
Sequential Administration of WJ-MSCs for the Treatment of GvHD Refractory to Second Line Treatment
Hematopoietic stem cell transplantation (HSCT) is the treatment of choice for malignant hemopathies, but highlights the limitations of long-term results due to the high toxicity of the procedure and the development of Graft…
- Trial name
- GvHD (NCT06304025)
- Testing
- Wharton's jelly mesenchymal stem cells (WJ-MSCs)
- Volunteers
- 10 people
- Sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
Hematopoietic Stem Cell Transplantation
Employment Support After Hematopoietic Stem Cell Transplantation
This is a feasibility study of a Work Support (WorkS) intervention designed to ameliorate employment challenges for people preparing to return to work after allogeneic stem cell transplantation.
- Trial name
- WorkS (NCT06494423)
- Testing
- Work Support (WorkS)
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- MGH Institute of Health Professions
Allogenic Bone Marrow Transplantation
Evaluation of the Clinical Outcome of Cyclosporine Short Infusion Versus Continuous Infusion Post Allogenic Stem Cell Transplantation
This study focuses on the basis for current immunosuppressive strategies in patients undergoing allogeneic haematopoietic stem cell transplantation at the bone marrow transplantation unit in Ain Shams university hospitals.
- Trial name
- NCT04575779
- Testing
- Cyclosporin with a daily dose of 3 mg/kg/day intravenously over 2 h (short infusion) every 12 h
- Where
- Egypt
- Volunteers
- 31 people
- Sponsor
- Shaymaa Mohammed El-Awady
Primary Biliary Cirrhosis
Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis
This disease is believed to be due to immune cells, cells which normally protect the body, but are now destroying the bile ducts in the liver. When the ducts are damaged, bile builds up in the liver and damages liver tissue.
- Trial name
- NCT00393185
- Testing
- Non-myeloablative Hematopoietic Stem Cell Transplantation
- Sponsor
- Richard Burt, MD
Chronic Myeloproliferative Disorders, Leukemia
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- Bu Flu TBI (NCT00245037)
- Testing
- therapeutic allogeneic lymphocytes, busulfan, cyclosporine
- Where
- United States
- Volunteers
- 147 people
- Sponsor
- OHSU Knight Cancer Institute
Hematologic Malignancies, Graft vs Host Disease
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant
The proposed research study is to test the drug vorinostat, in a new use as an additional medication, with other standard treatments for the prevention of severe acute graft versus host disease (GVHD).
- Trial name
- NCT00810602
- Testing
- reduced intensity, related donor stem cell transplant, tacrolimus (standard GVHD prophylaxis), mycophenolate (standard GVHD prophylaxis)
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pavan Reddy, MD
Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome
Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS
This phase I trial studies the side effects and maximum tolerated dose of yttrium Y 90 anti-cluster of differentiation 45 (CD45) monoclonal antibody BC8 (90Y-BC8) followed by donor stem cell transplant in treating patients with…
- Conditions
- Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia
- Trial name
- NCT01300572
- Testing
- Allogeneic Bone Marrow Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
The goal of this clinical research study is to learn if giving cytotoxic T lymphocytes (CTLs) can help control CMV when it reactivates (becomes active again) in patients who receive an allogeneic stem cell transplant.
- Trial name
- NCT02210065
- Testing
- Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- M.D. Anderson Cancer Center
MDS, Myelodysplastic Syndrome MDS
Study of Allogeneic Stem Cell Transplant in Myelodysplastic Syndrome Following Conditioning With Fludarabine and Total Body Irradiation 800 cGy
This is a single center phase II study of allogeneic stem cell transplantation in MDS who are unlikely to benefit from conventional therapy.
- Conditions
- MDS, Myelodysplastic Syndrome MDS, Myelodysplastic Syndrome (MDS), Myelodysplastic Syndrome
- Trial name
- NCT07896928
- Testing
- Allogeneic Stem Cell Transplant
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Ronald Paquette
Myelofibrosis
AlloHCT With PegINFa for Myelofibrosis
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis.
- Trial name
- ATIOM (NCT05535764)
- Testing
- Pegylated interferon alpha2a
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Utah
Sickle Cell Disease
A Reduced Toxicity Allogeneic Unrelated Donor Stem Cell Transplantation (SCT) for Severe Sickle Cell Disease
Majority of patients who are eligible for allogeneic HSCT for cure of severe sickle cell disease lack a matched family donor. This study aims for cure of sickle cell disease by performing unrelated donor (outside family)…
- Trial name
- NCT01279616
- Testing
- Fludarabine monophosphate, Rituximab, Busulfan
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Nationwide Children's Hospital
Non-Hodgkin's Lymphoma, Leukemia
Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
- Conditions
- Non-Hodgkin's Lymphoma, Leukemia, Multiple Myeloma, Acute Myeloid Leukemia
- Trial name
- NCT00709592
- Testing
- Thymoglobulin, Total-Body Irradiation, Allogeneic PBSCT or BMT
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Virginia Commonwealth University
Allogeneic Hematopoietic Cell Transplantation (HCT)
Fecal Microbiota Transplantation (FMT) in Recipients After Allogeneic Hematopoietic Cell Transplantation (HCT)
This research study is studying the role fecal microbiota transplantation may play in post-Hematopoietic Cell Transplantation (HCT) recipients
- Trial name
- NCT03720392
- Testing
- FMT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Zachariah Michael DeFilipp
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.